UBAC2 promotes bladder cancer proliferation through BCRC-3/miRNA-182-5p/p27 axis

Chaohui Gu1, Keyuan Zhao1, Naichun Zhou1, Feng Liu2, Fei Xie3, Shunli Yu1, Yongjie Feng1, Long Chen1, Jinjian Yang1, Fengyan Tian4 and Guosong Jiang2

Abstract
Emerging evidences have demonstrated that ubiquitin-associated domain-containing protein 2 (UBAC2) is closely related to the occurrence and development of malignant tumors. However, the functions and underlying molecular mechanisms of UBAC2 in bladder cancer (BC) development have not been defined. In this study, we found that both UBAC2 mRNA and protein levels were upregulated in BC tissues and cell lines, and knockdown of UBAC2 inhibited BC cells proliferation both in vitro and in vivo. Meanwhile, Kaplan–Meier survival plots of 406 BC cases from TCGA database showed that higher expression of UBAC2 in BC patients was associated with lower survival rate. Mechanistic studies revealed that knockdown of UBAC2 increased the expression of p27 by posttranscriptional regulation. Our previous study indicated that circular RNA BCRC-3 (BCRC-3) promoted the expression of p27 through interacting with miR-182-5p, and reversed miR-182-5p-induced inhibition of p27 3′UTR activity. In the present study, we found that UBAC2 could bind to BCRC-3, and subsequently affected the interaction of BCRC-3 with miR-182-5p to inhibit the expression of p27. Furthermore, knockdown of BCRC-3 partly reversed the upregulation of p27 expression induced by knockdown of UBAC2. Our findings highlight a novel mechanism of UBAC2 in regulating p27 through affecting the function of BCRC-3, and provide a research basis for the diagnostic and therapeutic application of BC.

Introduction
Bladder cancer (BC) is a common cancer in the world, with a high incidence and mortality rate1. In the United States, there were 80,470 (61,700 men; 18,770 women) new cases of BC and 17,670 deaths (12,870 men; 4800 women) by BC in 20192. The diagnosis and treatment technologies, including surgery, chemotherapy, and immunotherapy have been improved continuously3,4. However, the overall survival rate is still very low owing to various clinical characteristics and treatment responses caused by the complex pathogenesis of BC5. Therefore, further exploration of the regulatory mechanism involved in BC progression is necessary for the progress of diagnostic markers and novel effective therapies for BC patients.

The ubiquitin-associated domain-containing protein 2 (UBAC2) gene is located on chromosome 13q32.3 and encodes UBAC2 protein that is a highly conserved protein in different species6,7. It was reported that the polymorphism of UBAC2 gene was related to Behcet’s disease8–11. The upregulation of UBAC2 expression can promote the progression of Behcet’s disease11. Recently, a growing body of evidences demonstrated that UBAC2 was also closely related to the occurrence and development of malignant tumors, such as skin cancer and BC12,13. Moreover, it was reported that the expression level of UBAC2 was diverse in different types and pathological grades of BC by using microarray13. However, the specific role, regulatory
mechanisms and the upstream regulator/downstream effectors of UBAC2 in human BC are still unclear.

Circular RNAs (circRNAs), a new member of non-coding RNAs (ncRNAs), have been discovered about 40 years by electron microscopy. Previously, circRNAs were thought as by-products of splicing errors. However, the development of the high-throughout sequencing and bioinformatic analysis have identified and proved thousands of circRNAs in diverse species. Moreover, a lot of studies have demonstrated that circRNAs play crucial roles in many diseases such as neurological disorders, atherosclerotic vascular disease, carcinomas, and so on. Recently, increasing numbers of studies indicated that circRNAs could affect the functions of proteins via direct interactions with them. For instance, circRNAs could facilitate their nuclear or cytoplasmic localizations, regulate their functions or stability, promote or inhibit the interactions between them, or influence the interactions between them and DNA by binding directly with proteins. The biological roles of RNA–protein interactions are pervasive through direct or indirect interactions. However, little is known about the effect of proteins on the function of circRNAs.

In this research, we explored the expression level and potential role of UBAC2 in BC and found that UBAC2 was overexpressed and knockdown of UBAC2 inhibited BC cell lines proliferation by promoting the expression of p27 in vitro and in vivo. In our recent study, we have demonstrated that BC related circRNA-3 (BCRC-3) can promote the expression of p27 through acting as “miRNA sponge” for miR-182-5p in BC cells. Our further analyses indicated that UBAC2 could increase the expression of p27 through affecting the interaction of BCRC-3 with miR-182-5p in BC cells and then affected the progression of BC. Collectively, we found a novel mechanism of UBAC2 affecting the function of BCRC-3, and UBAC2 may serve as a novel promising target for diagnosis and therapy of BC.

Materials and methods
Patient tissue specimens and cell lines
All 48 specimens of BC tissues and their adjacent normal tissues were obtained from patients undergoing radical cystectomy at the Department of Urology of Union Hospital affiliated of Tongji Medical College. Human specimen collection was approved by the Institutional Review Board of Tongji Medical College of Huazhong University of Science and Technology. All tissues were confirmed and classified by more than one experienced pathologist according to the 2004 World Health Organization Consensus Classification and Staging System for bladder neoplasms. Clinicopathological features of patients are listed in Table S1. The human BC cell lines (RT4, EJ, UMUC3, and T24) and human normal urothelial cell line (SV-HUC-1) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The human BC cell line T24T was provided by Dr. Dan Theodorescu (Departments of Urology, University of Virginia, Charlottesville, VA). All cell lines were cultured at 37 °C and 5% CO2 with RPMI-1640 medium (Gibco, Grand Island, NY, USA) plus 10% fetal bovine serum (Gibco, Australia origin) and 1% penicillin–streptomycin (Gibco).

RNA extraction and PCR assays
Total RNA of tissue samples and cell lines were extracted by TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. Complementary DNA synthesized using the HiScript III RT SuperMix for quantitative polymerase chain reaction (qPCR) (Vazyme Biotech, Nanjing, China) with random or oligo(dT) primer. Then, the quantitative real-time PCR (qRT-PCR) was performed using SYBR Green Master Mix (Vazyme Biotech). β-actin or U6 was used as internal control when calculation using the ΔΔCt method. All data were analyzed using the StepOnePlus Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). All primers were obtained from RiboBio (Guangzhou, China). The primers are listed in Table S3.

Western blotting analysis
Total protein was extracted from RIPA lysis buffer (Invitrogen) and the concentration was determined using the BCA Protein Assay Kit (Beyotime, Shanghai, China). The protein samples were separated by SDS-PAGE gels and then transferred onto polyvinylidene difluoride membranes. After blocked for 1 h at room temperature, membranes were probed with primary antibodies overnight at 4 °C. Then, membranes were incubated for 1 h in the specific horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature. All images were developed by ECL kit (Servicebio, Wuhan, China) and obtained by using BioSpectrum600 Imaging System (UVP, CA, USA). Antibodies against UBAC2 (Cat No: 25122-1-AP), CDK2 (Cat. No. 10122-1-AP), CDK4 (Cat. No: 11026-1-AP), CDK6 (Cat. No:14052-1-AP), cyclin D1 (Cat. No. 60186-1- Ig), Cyclin E (Cat. No: 11554-1-AP), p21 (Cat. No: 10355-1-AP), p27 (Cat. No: 25614-1-AP), β-actin (Cat. No: 60008-1-Ig), HRP-conjugated secondary goat anti-mouse (Cat. No: SA00001-1) and goat anti-rabbit (Cat. No: SA00001-2) were purchased from Proteintech Group (Chicago, USA).

Plasmids construction and stable transfection
The shRNAs targeting UBAC2 (shUBAC2) and BCRC-3 (shBCRC-3) were synthesized by Genechem (Shanghai, China), and were cloned into GV298 vector (Table S4).
ShRNAs targeting p27 were obtained from our previous study. The plasmids were transfected into cells by using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s instructions. The transfected cells were selected with puromycin (Invitrogen) for 3–4 weeks. The sequence of shRNAs targeting UBAC2 and BCRC-3 are shown in Table S3.

**Immunohistochemistry analysis**

Immunostaining was carried out on BC tissue sections from patients and tumor tissues from xenografts in nude mice, with specific antibodies for UBAC2, p27, and Ki-67 (Cat. No. 27309-1-AP, respectively (Proteintech). An Olympus FFX100 microscope (Olympus, Japan) was used to capture images. The IHC stained sections were evaluated at 400-fold magnification, and 4–6 representative staining fields of each section were analyzed. The protein expression levels were analyzed by calculating the integrated optical density per stained area (IOD/area) using Image-Pro Plus version 6.0 (Media Cybernetics, MD, USA) as described.

**Immunofluorescence (IF) analysis**

Immunofluorescence (IF) analysis was carried out as described. Antibody against UBAC2 was purchased from Proteintech Group (Wuhan, China). The FITC-conjugated Goat Anti-Mouse IgG (Cat. No. GB22301) and DAPI obtained from Servicebio (Wuhan, China). All images were obtained using Nikon A1Si Laser Scanning Confocal Microscope (Nikon Instruments Inc., Japan).

**Flow cytometry assay for the cell cycle**

EJ and UMUC3 cells stably transfected with plasmids were harvested to analyze cell cycle by flow cytometry (Becton Dickinson, NJ, USA) after stained with propidium iodide buffer (BD Pharmingen). The results were analyzed with ModFit LT software.

**Cell Counting Kit-8 (CCK-8) assay**

Cell viability was detected by using Cell Counting Kit-8 assay. Cells stably transfected with plasmids were cultured in 96-well plates until cell confluence reached 60%. Then, a volume of 10 µl of CCK-8 solution (Servicebio) was added to each well at 0, 24, 48, and 72 h. After incubation for 2 h, the absorbance at 450 nm was measured using spectrometer (Thermo Fisher Scientific, MA, USA).

**Colony formation assay**

For the colony formation assay, EJ and UMUC3 cells stably transfected with plasmids were seeded in 6-wells plates at density of 600 cells per well and cultured for 2 weeks. The cell colonies were fixed with 4% poly-formaldehyde for 30 min and stained with 0.1% crystal violet (Servicebio) for another 20 min at room temperature. Cell colonies with more than 50 cells were counted.

**Tumor xenografts**

All animal experiments were approved by the Animal Care Committee of Tongji Medical College (approval no. 20192289). Four-week-old male nude mice from the Institute of Zoology (Beijing, China) were selected for tumor xenografts and randomly divided into two groups (n = 5 per group). EJ cells stably transfected with shUBAC2 plasmids or control plasmids were subcutaneously injected into the right flanks of the nude mice (2 × 10⁶, 200 µL), respectively. The volumes of tumors were measured at 1–4 weeks after injection and measured as the length × width² × 0.5.

**RNA immunoprecipitation (RIP) assay**

RNA immunoprecipitation (RIP) assay was performed as described. In brief, about 1.5 × 10⁷ cells were harvested and lysed to extract total protein. Total protein was immunoprecipitated with antibody against UBAC2 purchased form Proteintech Group (Cat. No. 25122-1-AP) or IgG antibody as control, and Protein A/G magnetic beads (Life Technologies). Finally, the RNA complexes combining on the protein were purified with RNeasy Mini Kit (QIAGEN, China) for RT-PCR.

**Pull-down assay with biotinylated BCRC-3 probe**

Biotinylated-BCRC-3 probe was synthesized by RiboBio. The sequence of the BCRC-3 probe was just complemented to the back-spliced junction of circular BCRC-3 and listed in Table S3. Pull-down assay was performed as our previous study. The RNeasy Mini Kit (QIAGEN, China) was used to extract the bound RNAs for further research.

**Luciferase reporter assay**

The p27 3’UTR or promoter reporters were transiently transfected into BC cells together with Renilla control plasmid, concomitantly either with shUBAC2, or shNC. After 24 h, the luciferase activity was determined following dual luciferase reporter assay detection kit (Promega, WI, USA).

**RNA fluorescence in situ hybridization**

Cy3-labeled BCRC-3 probe was bought from RiboBio. The assay was performed using fluorescence in situ hybridization kit (RiboBio, Guangzhou, China) according to the manufacturer’s instructions. The signal of the probes was detected by Nikon A1Si Laser Scanning Confocal Microscope (Nikon Instruments Inc., Japan).

**Statistical analysis**

All data were analyzed using GraphPad Prism 7.0 (La Jolla, USA). The group difference was evaluated by student’s t-test or chi-square, presented as means ± standard error of the mean (SEM). Kaplan–Meier survival curve and log-rank test were employed to depict the OS distributions of BC patients with different expression levels of UBAC2. P < 0.05 was considered statistically significant.
Results

UBAC2 is overexpressed in BC tissues and cell lines

In order to evaluate the expression level of UBAC2 in BC, we analyzed 48 pairs of urothelial carcinoma of bladder tissues and surrounding normal bladder tissues by qRT-PCR assay. As shown in Fig. 1a, the mRNA level of UBAC2 was significantly upregulated in BC tissues. Moreover, immunohistochemistry analysis showed that the expression level of UBAC2 protein was remarkably higher in BC tissues than that in adjacent normal tissues (Fig. 1b). Nevertheless, the expression of UBAC2 had no relationship with BC grade, pathological stage and lymph

![Diagram](image_url)

Fig. 1 UBAC2 is overexpressed in BC tissues and cell lines. a The results from qRT-PCR analysis showed that the mRNA expression levels of UBAC2 were significantly upregulated in BC tissues compared with their adjacent normal tissues. β-actin was used as loading control. b The protein expression levels of UBAC2 in 12 samples were determined by immunohistochemistry (IHC) staining and analyzed by calculating the integrated optical density per stained area (IOD/area). The tumor sample shown here is stage T3 with high grade. c-d The mRNA (c) and protein (d) levels of UBAC2 in SV-HUC-1, RT4, EJ, UMUC3, T24, and T24T cells were validated by qRT-PCR and western blotting. β-actin was used as loading control. e Kaplan-Meier survival plots of 48 bladder cancer cases from our hospital show the survival probability of patients with high or low expression of UBAC2 (p = 0.030, log-rank test). f Kaplan-Meier survival plots of 406 bladder cancer cases from TCGA database show the survival probability of patients with high or low expression of UBAC2 (n = 406, p = 0.035, log-rank test). g Immunofluorescence (IF) showed that UBAC2 protein stained green was localized in cytoplasm of BC cells. Nuclei were stained blue with DAPI (scale bar, 10 μm). Data are presented as mean ± SEM from three independent replicates. *P < 0.05; **P < 0.01; ***P < 0.001 (Student’s t test).
Fig. 2 (See legend on next page.)
node metastasis (Tables S1 and 2). Besides, higher expression levels of both UBAC2 mRNA and protein were also detected in RT4, EJ, UMUC3, T24, and T24T BC cell lines as compared with human immortalized uroepithelium cells SV-HUC-1 (Fig. 1c, d). Kaplan–Meier survival plots of 48 BC cases from our hospital (Fig. 1e) and 406 BC cases from TCGA database suggested that patients with higher UBAC2 expression had worse survival probability (Fig. 1f). The images from IF analysis showed that UBAC2 was mainly localized in the cytoplasm of BC cells (Fig. 1g). These results indicated that UBAC2 might promote BC progression.

Knockdown of UBAC2 represses the proliferation of BC cells in vitro and in vivo

In order to explore the function of UBAC2 in BC cells, we selected EJ and UMUC3 cells with the highest expression of UBAC2 for the further experiments. Meanwhile, four shRNAs targeting the coding region of UBAC2 (shUBAC2) were designed and stably transfected into EJ and UMUC3 cells with puromycin antibiotic selection. The efficiency of UBAC2 knockdown was detected by qRT-PCR and western blotting (Fig. 2a, b). We finally selected shUBAC2-1 and shUBAC2-3 for further studies because of their obvious knockdown effects. The cell cycle assay suggested that knockdown of UBAC2 resulted in cell cycle arrest at G0/G1 phase in EJ and UMUC3 cells (Fig. 2c). Besides, we found that the growth rate of both EJ and UMUC3 cells stably transfected with shUBAC2 decelerated significantly through CCK8 assay (Fig. 2d). Consistently, plate clone formation assay indicated that knockdown of UBAC2 remarkably suppressed the growth capability of EJ and UMUC3 cells (Fig. 2e). Nevertheless, the results from transwell migration assay and apoptosis assay showed that knockdown of UBAC2 did not affect the migration and apoptosis of EJ or UMUC3 cells (Fig. S1a, b).

To further explore the biological function of UBAC2 in vivo, nude mice were injected with EJ cells stably transfected with shUBAC2 or control plasmids. The results indicated that the growth rate and the weight of xenograft tumors derived from shUBAC2 stable transfectants decreased significantly compared with control group (Fig. 2f–i). Moreover, knockdown of UBAC2 significantly reduced the expression level of the proliferation marker Ki-67 (Fig. 2j). Collectively, these findings demonstrated that UBAC2 played an oncogenic role through promoting proliferation and cell cycle progression in BC cells.

Knockdown of UBAC2 inhibits BC cells proliferation through increasing the expression of p27

To determine the molecular mechanism of UBAC2 that promoted BC cells proliferation, we detected the potential interactions between UBAC2 and a series of key proteins related to cell cycle by western blotting assay. The key proteins included cyclin D1, cyclin E, CDK2, CDK4, CDK6, p27, and p21, and the results showed that p27 was the only upregulated protein in shUBAC2 stable transfectants (Fig. 3a). Meanwhile, knockdown of UBAC2 also induced the upregulation of p27 mRNA expression (Fig. 3b). Consistently, the efficiency of UBAC2 knockdown was also obvious in vivo, and we found that both protein and mRNA expression levels of p27 in xenograft tumors from shUBAC2 group were significantly higher than that from control group (Fig. 3c, d).

We further examined whether p27 was involved in shUBAC2-induced cell cycle arrest. The shRNAs targeting p27 (shP27) were obtained from our previous study and shP27-2 was finally selected for further studies owing to its better knockdown effect (Fig. S2a, b). We found that cell cycle progression was promoted by knockdown of p27 in BC cells (Fig. 3e, f). Furthermore, shUBAC2-induced cell cycle arrest was partially reversed by knockdown of p27 (Fig. 3e, f). Based on these results, we confirmed that knockdown of UBAC2 could suppress cell proliferation via increasing the expression of p27.

UBAC2 can directly bind to circular RNA BCRC-3

In order to explore how UBAC2 affected the expression of p27, the p27 3′-UTR and promoter luciferase reporter
Fig. 3 Knockdown of UBAC2 increases the expression of p27. a The expression levels of cell cycle related proteins (cyclin D1, cyclin E, CDK2, CDK4, CDK6, p27, and p21) were analyzed by western blotting after transfection with shUBAC2 or shNC in EJ and UMUC3 cell lines. β-actin was used as loading control. b The results from qRT-PCR showed that knockdown of UBAC2 significantly promoted the mRNA expression of p27 in EJ and UMUC3 cell lines. β-actin was used as loading control. c The protein expression level of UBAC2 and p27 in xenograft tumors was detected by immunohistochemistry (IHC) staining and analyzed by calculating the integrated optical density per stained area (IOD/area). d The mRNA expression level of UBAC2 and p27 in xenograft tumors from nude mice was determined by qRT-PCR. e, f Cell cycle distributions in shNC group, shUBAC2-3 group, shP27 group and shUBAC2-3 + shP27 group were presented by flow cytometry. Data are presented as means ± SEM from three independent replicates or as means ± SEM of five mice from each group. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
Fig. 4 (See legend on next page.)
assays were performed. The results showed that knockdown of UBAC2 significantly amplified the activity of p27 3′-UTR in EJ and UMUC3 cells, while the activity of p27 promoter was not affected (Fig. 4a). Similarly, our previous studies demonstrated that BCRC-3 could promote the expression of p27 through binding with miR-182-5p and preventing it from blocking p27 3′UTR activity.

We next investigated whether UBAC2 affected the expression of BCRC-3 or miR-182-5p and then affected the expression of p27. Nevertheless, the results from qRT-PCR suggested that the expression levels of BCRC-3 or miR-182-5p were not significantly affected by knockdown of UBAC2 in EJ and UMUC3 cells (Fig. 4b, c). Meanwhile, we analyzed the expression of BCRC-3 and miRNA-182-5p in xenograft tumors by qRT-PCR and found the same results (Fig. S3a, b).

Then, we performed RIP to identify whether UBAC2 could directly bind to BCRC-3. The RIP efficiency was detected by western blotting (Fig. 4d) and the results from qRT-PCR showed that BCRC-3 was the only one that antiUBAC2 antibody abundantly immuno-precipitated in the six noncoding RNAs we have studied before, including BCRC-3, circNR3C1, circHIPK3, MEG3, SPRY4-IT1, and GAS5 (Fig. 4e). Meanwhile, RNase R was used to pretreat lysates from UBAC2 immunoprecipitation assay and the results from qRT-PCR showed that the BCRC-3 pulled down was circular (Fig. 4f). To further confirm the direct binding of UBAC2 and BCRC-3, we performed RNA pull-down assay and the pull-down efficiency was shown in Fig. 4g. The results from western blotting and silver staining suggested that UBAC2 was considerably pulled down by the BCRC-3 probe (Fig. 4h, i). Consistently, the merged images derived from IF and FISH detection demonstrated that UBAC2 and BCRC-3 were co-localized in the cytoplasm of BC cells, and the same results were found in EJ cells stably transfected with shUBAC2 (Fig. 4j and Fig. S4a, b). The above results indicated that UBAC2 could directly bind to BCRC-3 in BC cells.

Knockdown of UBAC2 increases the expression of p27 through affecting the interaction of BCRC-3 with miR-182-5p in BC cells

We further investigated whether the combination of UBAC2 and BCRC-3 affected the interaction of BCRC-3 with miR-182-5p by using pull-down assay. The results showed that the BCRC-3 probe pulled down significantly more miR-182-5p upon knockdown of UBAC2 in EJ and UMUC3 cells (Fig. 5a). Importantly, the increased effects of shUBAC2 on both the protein and mRNA expression levels of p27 were partly reversed upon knockdown of BCRC-3 in EJ and UMUC3 cells (Fig. 5b, c). The efficiency of BCRC-3 knockdown was shown in Fig. S2c, and we ultimately selected shBCRC-3-3 for further studies because of its better knockdown effect. Consistently, shUBAC2-induced cell cycle arrest was partly reversed upon knockdown of BCRC-3 (Fig. 5d, e). Moreover, ectopic expression of miR-182-5p partly reversed the increased expression of p27 and cell-cycle arrest induced by UBAC2 inhibition (Fig. 6a–d). Taken together, these results demonstrated that UBAC2 could regulate the expression of p27 through affecting the interaction of BCRC-3 with miR-182-5p in BC cells (Fig. 7).

Discussion

The biological roles of RNA-protein interactions are pervasive. Especially the effects of RNA binding proteins (RBPs) on RNAs, are key aspects of many cellular processes that go beyond the already established steps of the mRNA production and usage as information carriers, including splicing, polyadenylation, transport, stability and translation. RBPs have been studied for decades, yet our understanding of RBPs is mainly limited to proteins with known or predicted RNA-binding domains (RBDs), which are considered to be the major proteins interacting with RNA. Recently, 555 proteins constituting the mouse embryonic stem cells mRNA interactome were defined. Strikingly, 216 of the 555 mRNA interactome proteins (39%) do not carry any known RBDs.
Fig. 5 Knockdown of UBAC2 affects the interaction of BCRC-3 with miR-182-5p in BC cells. a The expression level of miR-182-5p was determined by qRT-PCR in EJ and UMUC3 transfected with shUBAC2-3 or shNC lysates after biotin-BCRC-3 pull-down assay. U6 was used as negative control. Relative level of miR182-5p was normalized to input. b, c The protein (b) and mRNA (c) expression levels of p27 in the EJ and UMUC3 after co-transfection with shUBAC2-3 and shBCRC3. β-actin was used as loading control. d, e Distribution of cell population in G1, S, and G2 phase in shNC group, shUBAC2-3 group, shBCRC3 group and shUBAC2-3 + shBCRC3 group. Data are presented as means ± SEM from three independent replicate experiments. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
in mouse embryonic stem cells. Additionally, more than 300 novel RNA-binding proteins were also defined in HeLa and HEK293 cells and a lot of these proteins do not contain canonical RBDs. Recent study has demonstrated that TRIM25, a member of the Tripartite Motif (TRIM) family of E3 ubiquitin ligases without canonical RNA-binding domain, can act as a novel RNA-binding protein to directly interact with mRNA. Furthermore, a growing knowledge of RBPs targets is shifting the attention towards non-coding RNAs, from RNAs involved in the translation machinery and its regulation (rRNAs, tRNAs, small interfering RNAs and miRNAs) to lncRNAs and circRNAs. For instance, the cell cycle proteins cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase inhibitor 1 (p21) can bind to circ-Foxo3, resulting in the formation of a ternary complex. It has been reported that the E3 ubiquitin ligase CUL4A without RBD can interact with lncRNA uc.134 to form a RNP.
Circular RNAs (circRNAs), attracting great attentions for their closed continuous loop structure and potential value in clinical work, are produced from precursor mRNA (pre-mRNA) back-splicing of thousands of genes in eukaryotes. RBPs have been reported to regulate the biogenesis of circRNAs through direct binding to circRNAs. For instance, the splicing factor Muscleblind (Mbl) regulates circRNA production from its own pre-mRNA through specific and direct binding to conserved muscleblind binding sites of circRNA (circMbl). The RBP Quaking (QKI) can regulate the formation of circRNAs by binding to two flanking introns and bring the circularized exons closer together, resulting in upregulation of circRNAs production in human epithelial–mesenchymal transition (EMT). In addition, RBPs also regulate the degradation of circRNAs. For instance, GW182, a key component of P-body and RNAi machine, plays a crucial role in the process of circRNAs degradation through mediating the interactions between circRNAs and circRNA decay factors. However, we found that the expression level of BCRC-3 was not affected by UBAC2 in this study. Subsequently, we explored whether the function of BCRC-3 was affected by UBAC2, and found that UBAC2 could affect the inhibition of BCRC-3 on the proliferation of BC cells. On the other hand, previous studies have reported that circRNAs can affect the functions of proteins via direct interaction with them. It has been reported that UBAC2 can negatively regulate the canonical Wnt signaling pathway in the lymphocytes by promoting the ubiquitin-mediated degradation of CTNNB1 and Wnt receptors FZD6 and LRP6, and restrict trafficking of UBXD8 from the endoplasmic reticulum to lipid droplets. Whether the function of UBAC2 are affected by BCRC-3, is deserved our further investigation. On the other hand, the regulatory mechanism of tumorigenesis and development is complex, and many regulatory pathways are intertwined. One molecule may participate in multiple regulatory pathways. In the future research, we will further explore ubiquitin related regulatory mechanism of UBAC2 in BC.

To date, numerous functions of circRNAs have been discovered, such as modulating parental gene expression, regulating alternative splicing, acting as miRNA sponges, acting as protein sponges or protein scaffolds, and so on. Among them, a well-defined function of circRNAs is binding with microRNAs (miRNAs) and sequestering them away from their target mRNAs as competitive. In our previous study, we have identified that BCRC-3, circHIPK3, circNR3C1, and circ001361 can act as “miRNA sponge” to regulate the progress of BC. In these circRNAs, BCRC-3 inhibits BC cells proliferation through acting as “miRNA sponge” for miR-182-5p to promote the expression of p27. In the present study, we found that p27 was also the effector molecule of UBAC2 in regulation BC cells proliferation. P27(Kip1) is a member of the KIP/CIP family of cyclin/cyclin-dependent kinase (CDK) inhibitors and regulates cell-cycle progression at the G1 to S phase transition. A lot of studies showed that the expression of p27 protein were reduced in many tumors, including colon cancer, lung cancer, prostate cancer, breast cancer, and some hematological malignancies. In BC, induction of p27 is frequently found to be involved in inhibition of BC cells proliferation and decreased p27 expression is associated with poor overall and post-relapse survival. The expression of p27 can be regulated by transcriptional and posttranscriptional mechanisms. In this research, we demonstrated that UBAC2 participated in the post transcriptional regulation of p27 through affecting the interaction of BCRC-3 with miR-182-5p. Our findings further extend the upstream regulatory network of post transcriptional regulation of p27 in BC cells.

In summary, we demonstrate that both mRNA and protein levels of UBAC2 are upregulated in BC tissues and cell lines for the first time, and the expression of UBAC2
is significantly correlated with the overall survival of patients. Furthermore, we find that knockdown of UBAC2 can inhibit BC cells proliferation by increasing the expression of p27, and UBAC2 can directly bind with BCRC-3. Finally, our results show that UBAC2 can inhibit the expression of p27 through BCRC-3/miRNA-182-5p/p27 axis, thus promote the proliferation of BC cells. Our results not only explain the potential mechanisms related to UBAC2 in regulation BC cells proliferation, but they also provide a potential attractive target for diagnosis and therapy of BC.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Nos. 81100464, 81200883, 81772724, 81974396, and 81570685), National Science Foundation of Henan Province (No. 2018061), the Medical Key Technologies R&D Program of Henan (No. 201702301 and 201702015) and the Key Program of the Higher Education Institutions of Henan Province, China (Nos. 20A320032 and 20A320044).

Author details

1Departments of Urology, Henan Institute of Urology and Zhengzhou Key Laboratory for Molecular Biology of Urological Tumor Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China. 2Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhu 430022, China. 3Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao 266013, China. 4Departments of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanied this paper at [https://doi.org/10.1038/s41419-020-02935-7](https://doi.org/10.1038/s41419-020-02935-7).

Received: 18 December 2019 Revised: 19 August 2020 Accepted: 24 August 2020

Published online: 10 September 2020

References

1. Antoni, S. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol. 71, 98–108 (2017).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
3. Flagg, T. W. et al. NCCN guidelines insights: bladder cancer, version 2.2018. J. Natl Compr. Canc. Netw. 16, 1041–1053 (2018).
4. Mari, A., Abularrage, M., Gust, K. M. & Shariat, S. F. Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature. Curr. Opin. Urol. 28, 214–218 (2018).
5. Inamura, K. Bladder cancer: new insights into its molecular pathology. Cancers 10, 100 (2018).
6. Christianson, J. C. et al. Defining human ERAD networks through an integrative mapping strategy. Nat. Cell Biol. 14, 95–105 (2011).
7. Wang, Z. et al. Arabidopsis endoplasmic reticulum-localized UBAC2 proteins interact with PAMP-INDUCED COLEO-COIL to regulate pathogen-induced callose deposition and plant immunity. Plant Cell 31, 153–171 (2019).
8. Fei, Y. et al. Identification of novel genetic susceptibility loci for Behcet’s disease using a genome-wide association study. Arthritis Res. Ther. 11, R66 (2009).
9. Hou, S. et al. Replication study confirms the association between UBAC2 and Behcet’s disease in two independent Chinese sets of patients and controls. Arthritis Res. Ther. 14, R70 (2012).
10. Savalhia, A. H. et al. A putative functional variant within the UBAC2 gene is associated with increased risk of Behcet’s disease. Arthritis Rheum. 63, 3667–3672 (2011).
11. Yamazoe, K. et al. Comprehensive analysis of the association between UBAC2 polymorphisms and Behcet’s disease in a Japanese population. Sci. Rep. 7, 742 (2017).
12. Nan, H. et al. Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum. Mol. Genet. 20, 3718–3724 (2011).
13. Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27–42 (2016).
14. Hsu, M. T. & Coca-Prados, M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 280, 339–340 (1979).
15. Sanger, H. L., Klotz, G., Resner, D., Gross, H. J. & Kleinschmidt, A. K. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc. Natl Acad. Sci. USA 73, 3852–3856 (1976).
16. Cocquerelle, C., Mascrez, B., Hertil, D. & Balleul, B. Mis-slicing yields circular RNA molecules. FASEB J. 7, 155–160 (1993).
17. Jekc, W. R. et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19, 141–157 (2013).
18. Rybak-Wolf, A. et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol. Cell 58, 870–885 (2015).
19. Salzmann, J., Chen, R. E., Olsen, M. N., Wang, P. L. & Brown, P. O. Cell-type specific features of circular RNA expression. PLoS Genet. 9, e1003777 (2013).
20. Hansen, T. B. et al. Natural RNA circles function as efficient microRNA sponges. Nature 495, 384–388 (2013).
21. Holdt, L. M. et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat. Commun. 7, 12429 (2016).
22. Zheng, Q. et al. Circular RNA profiling reveals an abundant cichIPK3 that regulates cell growth by sponging multiple miRNAs. Nat. Commun. 7, 11215 (2016).
23. Luo, J., Liu, H., Luan, S. & Li, Z. Guidance of circular RNAs to proteins behavior as binding partners. Cell Mol. Life Sci. 76, 4233–4243 (2019).
24. Chen, Y. et al. Circular RNA cirAGO2 drives cancer progression through facilitating HuR-repressed functions of AGO2-miRNA complexes. Cell Death Differ. 26, 1346–1364 (2019).
25. Yang, Q. et al. A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ. 24, 1609–1620 (2017).
26. Abdelmohsen, K. et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 14, 361–369 (2017).
27. Zhou, L. Y. et al. The circular RNA ACR attenuates myocardial ischemia/reperfusion injury by suppressing autophagy via modulation of the Pim1/FAN1 pathway. Cell Death Differ. 26, 1299–1315 (2019).
28. Du, W. W. et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK4. Nucleic Acids Res. 44, 2846–2858 (2016).
29. Chen, N. et al. A novel Fli1 eicastic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1. Genome Biol. 19, 1–14 (2018).
30. Xia, P. et al. A circular RNA protects dormant hematopoietic stem cells from DNA sensor cGAS-mediated exhaustion. Immunity 48, 688–701 (2018).
31. Gangobey, Z. T. & Wickiens, M. Probing RNA-protein networks: biochemistry meets genomics. Trends Biochem. Sci. 40, 157–164 (2015).
32. Xie, F. et al. Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis. Mol. Cancer 17, 144 (2018).
33. Huang, H. et al. PHLP2 downregulation contributes to lung carcinogenesis following Flna/Rb(A)FPE exposure. Clin. Cancer Res. 21, 3783–3793 (2015).
34. Donaldson, J. G. Immunofluorescence staining. Curr. Protoc. Cell Biol. 69, 431–437 (2015).
35. Conn, S. J. et al. The RNA binding protein quaking regulates formation of circRNAs. Cell 160, 1125–1135 (2015).
36. Li, Y. et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep. 18, 1646–1659 (2017).
37. Jiang, G. et al. Transcriptional and post-transcriptional upregulation of p27 mediates growth inhibition of isopentagonenol (52) on human bladder cancer cells. Cancers 39, 482–492 (2018).
38. Lukong, K. E., Chang, K. W., Khandjian, E. W. & Richard, S. RNA-binding proteins in human genetic disease. Trends Genet. 24, 416–425 (2008).
39. Kishore, S., Luber, S. & Zavolan, M. Deciphering the role of RNA-binding proteins in the post-transcriptional control of gene expression. Brief Funct. Genomics 9, 391–404 (2010).
40. Licatalosi, D. D. & Darnell, R. B. RNA processing and its regulation: global insights into biological networks. Nat. Rev. Genet. 11, 75–87 (2010).
41. Singh, R. RNA-protein interactions that regulate pre-mRNA splicing. Gene Expr. 10, 79–92 (2002).
42. Kwon, S. C. et al. The RNA-binding protein repertoire of embryonic stem cells. Nat. Struct. Mol. Biol. 20, 1122–1130 (2013).
43. Castello, A. et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149, 1391–1406 (2012).
44. Balitz, A. G. et al. The RNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol. Cell 46, 674–690 (2012).
45. Choudhury, N. R. et al. RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination. BMC Biol. 15, 105–125 (2017).
46. Ferre, F., Colantoni, A. & Helmer-Citterich, M. Revealing protein-lncRNA interaction. Brief. Bioinform. 17, 106–116 (2016).
47. Du, W. W. et al. Identifying and characterizing circRNA-protein interaction. Theranostics 7, 4183–4191 (2017).
48. Liu, F. et al. A novel IncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LAT51. J. Hematol. Oncol. 10, 91–108 (2017).
49. Ivanov, A. et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 10, 170–177 (2015).
50. Ashwal-Fluss, R. et al. circRNA biogenesis competes with pre-mRNA splicing. Gene Expr. 10, 79–92 (2002).
51. Kramer, M. C. et al. Circular control of Drosophila circular RNA expression. Proc. Natl Acad. Sci. USA 110, 1345–1350 (2013).
52. Choudhury, N. R. et al. RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain and is required for ubiquitination. BMC Biol. 15, 105–125 (2017).
53. Ferre, F., Colantoni, A. & Helmer-Citterich, M. Revealing protein-lncRNA interaction. Brief. Bioinform. 17, 106–116 (2016).
54. Li, Z. et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 22, 256–264 (2015).
55. Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338 (2013).
56. Jeck, W. R. & Sharpless, N. E. Detecting and characterizing circular RNAs. Nat. Biotechnol. 32, 453–461 (2014).
57. Zheng, F. et al. CircRNA C1 inhibits proliferation of bladder cancer cells by sponging miR-27a-3p and downregulating cyclin D1 expression. Cancer Lett. 460, 139–151 (2019).
58. Liu, F. et al. Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. Oncogene 39, 1696–1709 (2020).
59. Thomas, G. V. et al. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am. J. Pathol. 153, 681–687 (1998).
60. Sukamoto, S. et al. Reduced expression of cell-cycle regulator p27Kip1 correlates with a shortened survival in non-cell lung cancer. Lung Cancer 34, 83–90 (2001).
61. Tsihlias, J. et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58, 542–548 (1998).
62. Ma, Z., Xue, S., Zeng, B. & Qu, D. IncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27. Oncol. Lett. 13, 1924–1930 (2018).
63. Han, S. et al. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res. Treat. 55, 161–167 (1999).
64. Miller, M. & Banerjee, S. p27 and leukemia: cell cycle and beyond. J. Cell. Physiol. 230, 504–509 (2015).
65. Miyake, M. et al. 1-tetrahydro-2-hydroxy-butyric acid (TBA), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27Kip1 and G1/S arrest. J. Pharmacol. Exp. Ther. 332, 795–802 (2010).
66. Yu, C. et al. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis 33, 678–686 (2012).
67. Korkolopoulou, P. et al. Cell cycle regulators in bladder cancer: a multitarget survival study with epico-p27Kip1. Hum. Pathol. 31, 751–760 (2000).